Rafael logo.png
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
May 26, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
March 30, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021 11:30 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 13, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 11:09 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
November 10, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 27, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan
October 20, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its...
Rafafel_Pharma_PHP_Graphic_Updated_V3
Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 21, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Rafafel_Pharma_PHP_Graphic_Updated_V3 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer...